市場調査レポート

世界の疼痛治療薬市場(第4版):市場動向および研究開発動向

The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights

発行 Arrowhead Publishers 商品コード 129394
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
世界の疼痛治療薬市場(第4版):市場動向および研究開発動向 The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights
出版日: 2010年11月19日 ページ情報: 英文

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当報告書では、疼痛管理市場の動向や課題、同分野に参入する主要企業プロファイルなどとともに、臨床開発段階および上市済みの主要製品に関する最新動向についてまとめ、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 疼痛:病気の背景

  • 疼痛のイントロダクション
  • 疼痛の分類
  • 疼痛の病態生理学
  • 免疫系と疼痛
  • 疼痛と遺伝子学
  • 世界の疼痛の影響

第3章 疼痛管理:WHOの疼痛治療薬クラスと治療ガイドライン

第4章 術後疼痛の概要と治療法

  • 術後疼痛の概要
  • 術後疼痛の疫学
  • 術後疼痛の治療管理
  • 主力ブランド
  • アンメットニーズ
  • パイプライン分析
  • 市場動向

第5章 神経因性疼痛市場

  • 神経因性疼痛の概要
  • 神経因性疼痛の疫学
  • 神経因性疼痛の治療管理
  • 主力ブランド
  • アンメットニーズ
  • パイプライン分析
  • 市場動向

第6章 線維筋痛市場

  • 線維筋痛の概要
  • 線維筋痛の疫学
  • 線維筋痛の治療管理
  • 主力ブランド
  • アンメットニーズ
  • パイプライン分析
  • 市場動向

第7章 関節痛市場

  • 関節痛の概要
  • 関節痛の疫学
  • 関節痛の治療管理
  • 主力ブランド
  • アンメットニーズ
  • パイプライン分析
  • 市場動向

第8章 片頭痛市場

  • 片頭痛の概要
  • 片頭痛の疫学
  • 片頭痛の治療管理
  • 主力ブランド
  • アンメットニーズ
  • パイプライン分析
  • 市場動向

第9章 癌疼痛市場

  • 癌疼痛の概要
  • 癌疼痛の疫学
  • 癌疼痛の治療管理
  • 主力ブランド
  • アンメットニーズ
  • パイプライン分析
  • 市場動向

第10章 腰痛市場

  • 腰痛の概要
  • 腰痛の疫学
  • 腰痛の治療管理
  • 主力ブランド
  • アンメットニーズ
  • パイプライン分析
  • 市場動向

第11章 疼痛治療薬研究開発動向

  • 治験概要
  • 動物疼痛モデル
  • 健康な人体における実験疼痛モデル
  • 機能的画像技術 他

第12章 疼痛治療薬市場におけるアンメットニーズ

  • 今日の鎮痛剤のニーズの高まりにおける臨床的効果
  • 現在の疼痛治療薬の安全プロファイルは不安定
  • 疼痛患者人口の見放し
  • 投薬療法の改善
  • 利便性の高い投与ルート
  • 動物疼痛モデルの有効性
  • 疼痛評価モデルの信頼性

第13章 疼痛治療薬パイプライン動向

第14章 疼痛治療薬市場分析

第15章 参考情報

図表

目次

Abstract

Pain continues to present numerous challenges to the biopharmaceutical industry. According to the American Academy of Pain Medicine, over 76 million Americans suffer from pain. Indeed, pain affects more Americans than cancer, diabetes and cardiac disease combined. Current analgesics only provide modest relief, frequently carry black box safety warnings and are susceptible to abuse.

The anticipated arrival of novel analgesics is set to transform this market. GW Pharmaceuticals' Sativex (GW-1000), Allergan' s Botox (botulinium toxin), Merck' s Telecagepant (MK-0974), Novartis' Canakinumab (ACZ885) and FoldRX Pharma' s Tafamidis (meglumine) will modernize pain management strategies. The market will enter a highly competitive, transitional era following the COX-2 saga. Investors must differentiate their products to gain blockbuster sales witnessed by Pfizer' s Lyrica (pregabalin) and Celebrex (celecoxib).

With numerous unmet needs, improved diagnosis of painful conditions, the advent of pharmacogenomics driving R&D and 10% of the global population regularly taking analgesia; the pain therapeutics market offers numerous lucrative commercial opportunities.

This in-depth report...

  • Analyzes seven major painful conditions examining epidemiology in the seven major markets, therapeutic management overview, unmet needs and pipeline analysis of each condition to maximize your product' s commercial success
  • Identifies the major challenges within pain R&D trends; exploring unmet needs, pain clinical trials, pharmacogenomics, animal pain models and functional imaging techniques
  • Analyzes both the clinical and commercial sides of the pain therapeutics market; including key late stage and Phase III/ II candidates and novel drug classes to watch

Report highlights

Although the analgesia market is highly competitive and heavily genericized, growth is expected. Improved diagnosis of fibromyalgia and neuropathic pain will be key driving factors. Sales of pain therapeutics could reach a massive $59 billion by 2015 in the seven major markets.

Biomarkers will transform pain R&D away from the traditional linear, over-simplified model approach. Novel analgesia drug targets will be realized, streamlining clinical trials and optimizing candidate' s efficacy and safety profiles.

Opioids will continue to form the backbone of pain relief due to improved physician prescribing confidence. By 2015, sales of opioids could reach $17 billion, with OxyContin (oxycodone; Purdue) remaining the top-selling branded analgesic until its patent expiration in 2013.

Reasons to buy this report

Assess opportunities and risks influencing pain R&D and regulatory approval trends Gain an impartial perspective of strategies that can be used to enhance your product' s performance in the pain therapeutics market Identify key pain therapeutic products in late-phase development Benchmark the competition via sales forecasts to 2015

Table of Contents

1 Executive Summary

  • 1.1 Scope of Global Pain Therapeutics Market, 4th Edition: Market Trends and R&D Insights
  • 1.2 Methodology of Global Pain Therapeutics Market, 4th Edition: Market Trends and R&D Insights
  • 1.3 The Epidemiology of Pain in the Seven Major Markets
  • 1.4 Unmet Needs in the Pain Therapeutics Market
  • 1.5 Pain Therapeutics Pipeline Analysis
  • 1.6 Pain Therapeutics Market Analysis

2 Pain: Disease Background

  • 2.1 An Introduction to Pain
  • 2.2 The Classification of Pain
    • 2.2.1 Acute Pain
    • 2.2.2 Chronic Pain
  • 2.3 The Pathophysiology of Pain
    • 2.3.1 The Pain Pathway
    • 2.3.2 The Modulation of the Pain Signal
    • 2.3.3 Referred Pain
  • 2.4 The Immune System and Pain
    • 2.4.1 Nerve Growth Factor (NGF)
    • 2.4.2 Brain Derived Neurotrophic Factor (BDNF)
    • 2.4.3 Nitrous Oxide (NO)
    • 2.4.4 Tumor Necrosis Factor (TNF)
    • 2.4.5 Interleukin-1 (IL-1)
    • 2.4.6 Glutamate
  • 2.5 Pain and Genetics
  • 2.6 The Subjective Nature of Pain
    • 2.6.1 The Evaluation of Pain
  • 2.7 The Global Impact of Pain
    • 2.7.1 The Financial Impact of Pain

3 Managing Pain: WHO' s Pain Therapeutics Classes and Treatment Guidelines

  • 3.1 Overview of the WHO' s Pain Therapeutics Classification
  • 3.2 M01A Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 3.3 M01B Anti-Inflammatory/Anti-Rheumatic Agents in Combination
  • 3.4 N01A General Anesthetics
  • 3.5 N01B Local Anesthetics
  • 3.6 N02A Narcotic Analgesics
  • 3.7 N02B Non-Narcotic Analgesics
  • 3.8 N02C Anti-Migraine Preparations
  • 3.9 Arrowhead' s Analgesic Dug Classification System
  • 3.10 WHO Pain Management Guidelines

4 The Postoperative Pain Market

  • 4.1 Overview of Postoperative Pain
  • 4.2 Epidemiology of Postoperative Pain
  • 4.3 The Therapeutic Management of Postoperative Pain
    • 4.3.1 Epidural Local Anesthetics Used in Postoperative Pain
    • 4.3.2 Strong Opioids Used in Postoperative Pain
    • 4.3.3 Weak Opioids Used in Postoperative Pain
    • 4.3.4 NSAIDs Used in Postoperative Pain
    • 4.3.5 Multi-Modal Analgesia Used in Postoperative Pain
  • 4.4 Leading Brand Products in the Postoperative Pain Market
    • 4.4.1 AstraZeneca/Abraxis BioScience' s Naropin (ropivacaine)
    • 4.4.2 J&J' s/Ortho McNeil - Janssen Pharmaceuticals Duragesic (transdermal fentanyl)
  • 4.5 Unmet Needs in the Postoperative Pain Market
  • 4.6 Postoperative Pain Therapeutics Pipeline Analysis
    • 4.6.1 Javelin Pharmaceuticals' Dyloject (Dicofenac Injection)
    • 4.6.2 Pfizer' s Lyrica (pregabalin)
    • 4.6.3 Paion' s Morphine-6-Gluconaride (M6G, intravenous morphine)
  • 4.7 Postoperative Pain Therapeutics Market Commentary

5 The Neuropathic Pain Market

  • 5.1 Overview of Neuropathic Pain
  • 5.2 Epidemiology of Neuropathic Pain
  • 5.3 The Therapeutic Management of Neuropathic Pain
    • 5.3.1 Topical Lidocaine Used in Neuropathic Pain
    • 5.3.2 Antidepressants Used in Neuropathic Pain
    • 5.3.3 Opioids Used in Neuropathic Pain
  • 5.4 Leading Brand Products in the Neuropathic Pain Market
    • 5.4.1 Endo Pharmaceuticals' Lidoderm (lidocaine 5%)
    • 5.4.2 Pfizer' s Lyrica (pregablin)
    • 5.4.3 Eli Lilly' s Cymbalta (duloxetine)
    • 5.4.4 Pfizer' s Neurontin (gabapentin)
    • 5.4.5 Novartis' Tegretol (carbamazepine)
  • 5.5 Unmet Needs in the Neuropathic Pain Market
  • 5.6 Neuropathic Pain Therapeutics Pipeline Analysis
    • 5.6.1 NeurogesX/Astellas Pharma' s Qutenza (capsaicin 8% patch, NGX-4010)
    • 5.6.2 EpiCepts' EpiCept NP-1 (amitriptyline/ketamine)
    • 5.6.3 FoldRx Pharmaceuticals' Tafamidis meglumine (Fx-1006A)
    • 5.6.4 Newron Pharmaceuticals' Ralfinamide
  • 5.7 Neuropathic Pain Therapeutics Market Commentary

6 The Fibromyalgia Market

  • 6.1 Fibromyalgia Overview
  • 6.2 Epidemiology of Fibromyalgia
  • 6.3 The Therapeutic Management of Fibromyalgia Pain
    • 6.3.1 Analgesics Used in Fibromyalgia
    • 6.3.2 Antidepressants Used in Fibromyalgia
    • 6.3.3 Muscle Relaxants Used in Fibromyalgia
    • 6.3.4 Sleep Modifiers Used in Fibromyalgia
    • 6.3.5 Anxiety Medications Used in Fibromyalgia
    • 6.3.6 Anticonvulsants Used in Fibromyalgia
    • 6.3.7 Antibiotics Used in Fibromyalgia
  • 6.4 Leading Brands in the Fibromyalgia Pain Market
    • 6.4.1 Pfizer' s Lyrica (pregabalin)
    • 6.4.2 Forest Laboratories/Cypress BioScience' s Savella (milnacipran)
    • 6.4.3 Eli Lilly' s Cymbalta (duloxetine)
  • 6.5 Unmet Needs in Fibromyalgia Pain Market
  • 6.6 Fibromyalgia Pain Pipeline Analysis
    • 6.6.1 Jazz Pharmaceuticals/UCB' s JZP-6 (sodium oxybate)
  • 6.7 Fibromyalgia Pain Market Commentary

7 The Arthritic Pain Market

  • 7.1 Arthritis Overview
  • 7.2 Epidemiology of Arthritic Pain
  • 7.3 The Therapeutic Management of Arthritic Pain
    • 7.3.1 Acetaminophen used in Arthritis
    • 7.3.2 NSAIDs Used in Arthritis
    • 7.3.3 COX-2 Inhibitors Used in Arthritis
    • 7.3.4 Disease Modifying Anti-Rheumatic Drugs (DMARDs) Used in Arthritis
    • 7.3.5 Biologic Disease Modifying Anti-inflammatory Drugs Used in Arthritis
    • 7.3.6 Corticosteroids Used in Arthritis
    • 7.3.7 Immunosuppressant' s used in Arthritis
  • 7.4 Leading Brands in the Arthritic Pain Market
    • 7.4.1 Pfizer Celebrex (celecoxib)
    • 7.4.2 Pfizer' s Arthrotec (diclofenac/misprostol)
    • 7.4.3 Boehringer Ingelheim/Abbott' s Mobic (meloxicam)
    • 7.4.4 Pfizer' s DayPro (oxarprozin)
  • 7.5 Unmet Needs in the Arthritic Pain Market
  • 7.6 Arthritic Pain Therapeutic Pipeline Analysis
    • 7.6.1 AstraZeneca/Pozen' s Vimovo (naproxen/esomeprazole)
    • 7.6.2 Pain Therapeutics/King Pharmaceuticals/Duracet' s Remoxy (oxycodone)
    • 7.6.3 Pfizer' s Tanezumab (PF-4383119)
    • 7.6.4 Novartis' Canakinumab (ACZ885)
    • 7.6.5 Janssen-Ortho-McNeil/Grunenthal GmbH' s Nucynta (tapentadol)
  • 7.7 Arthritic Pain Market Commentary

8 The Migraine Market

  • 8.1 Migraine Overview
  • 8.2 Epidemiology of Migraine
  • 8.3 The Therapeutic Management of Migraine
    • 8.3.1 Prophylactic Migraine Therapies
    • 8.3.2 Basic Analgesics Used in Migraine
    • 8.3.3 Ergot Alkaloid Derivatives Used in Migraine
    • 8.3.4 Triptans Used in Migraine
    • 8.3.5 Neuroleptics Used in Migraine
    • 8.3.6 Beta-Blockers Used in Migraine
  • 8.4 Leading Brand Products in the Migraine Market
    • 8.4.1 GSK' s Imitrex/Imigran (sumatriptan)
    • 8.4.2 AstraZeneca' s Zomig (zolmitriptan)
    • 8.4.3 Merck' s Maxalt (rizartriptan)
    • 8.4.4 Pfizer' s Relpax (eletriptan)
    • 8.4.5 GSK/Pozen' s Treximet (sumatripatan/naproxen)
    • 8.4.6 J&J/Ortho-McNeil' s Topamax (topiramate)
    • 8.4.7 Abbott' s Depakote (divalproex)
  • 8.5 Unmet Needs in the Migraine Market
  • 8.6 Migraine Therapeutics Pipeline Analysis
    • 8.6.1 Merck' s Telcagepant (MK-0974)
    • 8.6.2 Allergan' s Botox (botulinium toxin)
    • 8.6.3 MAP Pharmaceutical' s Levadex (MAP0004)
    • 8.6.4 NuPathe' s Zelrix (transdermal sumatriptan)
  • 8.7 Migraine Market Commentary

9 The Cancer Pain Market

  • 9.1 Cancer Pain Overview
  • 9.2 Epidemiology of Cancer Pain
  • 9.3 The Therapeutic Management of Cancer Pain
    • 9.3.1 Strong Opioids Used in Cancer Pain
    • 9.3.2 Weak Opioids Used in Cancer Pain
    • 9.3.3 NSAIDs and Acetaminophen Used in Cancer Pain
    • 9.3.4 Adjuvants Used in Cancer Pain
  • 9.4 Leading Brands in the Cancer Pain Market
    • 9.4.1 Cephalon Actiq (oral transmucosal fentanyl citrate)
    • 9.4.2 Cephalon' s Fentora (fentanyl buccal)
    • 9.4.3 Purdue' s OxyContin (oxycodone)
  • 9.5 Unmet Needs in the Cancer Pain Therapeutics Market
  • 9.6 Cancer Pain Therapeutics Pipeline Analysis
    • 9.6.1 Orexo/ProStrakan' s Abstral (fentanyl sublingual)
    • 9.6.2 Archimedes Pharmaceuticals' PecFent (nasal spray fentanyl)
    • 9.6.3 GW Pharmaceuticals' Sativex (GW-1000)
    • 9.6.4 Wex Pharmaceuticals' Tecin (tetrodotoxin)
  • 9.7 Cancer Pain Therapeutics Market Commentary

10 The Back Pain Market

  • 10.1 Back Pain Overview
  • 10.2 Epidemiology of Back Pain
  • 10.3 The Therapeutic Management of Back Pain
    • 10.3.1 NSAIDs Used in Back Pain
    • 10.3.2 Transdermal Patches Used in Back Pain
    • 10.3.3 Local Anesthetics Used in Back Pain
    • 10.3.4 Opioids Used in Back Pain
    • 10.3.5 Tricyclic Antidepressants Used in Back Pain
    • 10.3.6 Muscle Relaxants Used in Back Pain
    • 10.3.7 Colchicine Used in Back Pain
    • 10.3.8 Anticonvulsants Used in Back Pain
  • 10.4 Leading Brand Products in the Back Pain Market
    • 10.4.1 Bayer' s Aleve (naproxone)
    • 10.4.2 Novartis' Voltaren (diclofenac)
    • 10.4.3 Wyeth/Pfizer' s Advil (ibuprofen)
    • 10.4.4 BMS' Efferalgan (acetaminophen)
    • 10.4.5 Johnson &Johnson' s Tyenol (acetaminophen)
  • 10.5 Unmet Needs in the Back Pain Market
  • 10.6 Back Pain Pipeline Analysis
    • 10.6.1 Janssen-Ortho-McNeil Grunenthal GmbH' s Nucynta (tapentadol)
    • 10.6.2 Pfizer' s Tanzeumab
    • 10.6.3 EpiCept' s LidoPAIN BP (liodocaine topical patch)
  • 10.7 Back Pain Market Commentary

11 Pain Therapeutics Research and Development (R&D) Trends

  • 11.1 Overview of Clinical Trials
    • 11.1.1 Issues Surrounding the Design of Pain Therapeutic Clinical Trials
    • 11.1.2 Patient Selection
    • 11.1.3 Trial Duration
    • 11.1.4 Trial Comparator Drug Choice
    • 11.1.5 Trial End-Point
    • 11.1.6 Response Rates
    • 11.1.7 Quality of Life
    • 11.1.8 Adverse Events
    • 11.1.9 Biomarkers in R&D
    • 11.1.10 Predictive Biomarkers as Clinical Trial Surrogate Endpoints
    • 11.1.11 The Use of Biomarkers to Stratify Patients
    • 11.1.12 CYP2D6 Variants
    • 11.1.13 Potential Pain Biomarkers
    • 11.1.14 Arrowhead' s Recommendations for Maximizing Pain Therapeutics R&D
  • 11.2 Animal Pain Models
  • 11.3 Experimental Pain Models in Healthy Humans
    • 11.3.1 UV-B Pain Model
    • 11.3.2 Heat/Capsaicin Sensitization and Intradermal Capsaicin Injection Models
    • 11.3.3 Multi-Modal, Multi-Tissue Model
    • 11.3.4 Quantitative Sensory Testing
  • 11.4 Functional Imaging Techniques
    • 11.4.1 Functional Magnetic Resonance Imaging (fMRI)
    • 11.4.2 Positron Emission Tomography (PET)
    • 11.4.3 Single-Photon Emission Computed Tomography (SPECT)
  • 11.5 Laser Doppler Flowmetry (LDF)
  • 11.6 Abuse Liability and Safety/ Risk Evaluation and Mitigation Strategy (REMS)

12 Unmet Needs in the Pain Therapeutics Market

  • 12.1 Clinical Efficacy of Today' s' Analgesics Need Improving
  • 12.2 Safety Profiles of Current Pain Therapeutics are Often Unacceptable
  • 12.3 Certain Pain Patient Populations are Neglected
  • 12.4 Improved Dosing Regimens
  • 12.5 Convenient Administration Routes
  • 12.6 The Validity of Animal Pain Models
  • 12.7 The Reliability of Pain Evaluation Models

13 Pain Therapeutics Pipeline Watch

  • 13.1 Introduction to the Pain Therapeutics Pipeline
  • 13.2 Targeted Therapies
    • 13.2.1 Pfizer' s Tanezumab (PF-4383119)
  • 13.3 Purinoreceptor (P2X3 Receptor) Antagonists
    • 13.3.1 Afferent Pharmaceuticals P2X3 Program
  • 13.4 Cannabinoids
    • 13.4.1 Solvay Pharmaceuticals/Abbott' s Marinol (dronabinol)
    • 13.4.2 Valeant /Meda Pharmaceutical' s Cesamet (nabilone)
    • 13.4.3 Sanofi-Aventis' Acomplia /Zimulti (rimonabant)
    • 13.4.4 GW Pharmaceuticals' Sativex (GW-1000)
  • 13.5 Ion Channels
    • 13.5.1 Sodium Channel Blockers
    • 13.5.2 Wex Pharmaceuticals' Tectin (tetrodotoxin)
  • 13.6 Glutamate Receptor Antagonists
  • 13.7 NMDA-Receptor Antagonists
    • 13.7.1 King Pharmaceuticals/Forest Laboratories/Richter' s RGH-896
  • 13.8 NDMA and Opioid Receptor Overlap
  • 13.9 Dual Mu-Opioid Agonist and Nor epinephrine Reuptake Inhibitors
    • 13.9.1 Ortho-McNeil/Janssen Pharmaceuticals/Grunenthal GmbH' s Nucynta (tapentadol extended release)
  • 13.10 Calcitonin-Gene-Related Peptide (CGRP) Receptor Antagonists
    • 13.10.1 Merck' s Telcagepant (MK-0974)
  • 13.11 Pipeline Agents Designed with Convenient Administration Routes
    • 13.11.1 RoxRo Pharma Intranasal Ketorolac (ROX-888)
    • 13.11.2 NovaDel' s NovaMist Technology
    • 13.11.3 Depomed' s AcuForm Technology
    • 13.11.4 Durect Corp' s Transdur Technology
    • 13.11.5 Altea Therapeutics' Hydromorphone Patches

14 Analysis of the Pain Therapeutic Market

  • 14.1 Summary of Arrowhead' s Pain Therapeutics Analysis, 2010
  • 14.2 Leading Pain Therapeutic Products of 2009
  • 14.3 Leading Pain Therapeutics Drug Classes of 2010
  • 14.4 Leading Pain Therapeutics Drug Class Products of 2010
    • 14.4.1 COX-2 Inhibitors: Pfizer' s Celebrex (celecoxib)
    • 14.4.2 NSAIDs: Novartis' Voltaren (diclofenac)
    • 14.4.3 Local Anesthetics: Endo Pharmaceutical' s Lidoderm (lidocaine 5% patch)
    • 14.4.4 Narcotics: Purdue' s OxyContin (oxycodone)
    • 14.4.5 Triptans: GSK' s Imitrex/Imigran (sumatriptan)
    • 14.4.6 Nontraditional: Pfizer' s Lyrica (pregabalin)
  • 14.5 Pfizer: Arrowhead' s Leading Pain Therapeutics Company of 2009/2010
  • 14.6 SWOT Analysis of the Pain Therapeutics Market, 2010
  • 14.7 Financial Forecast of the Pain Therapeutics Market
    • 14.7.1 Financial Forecast of the Branded Pain Therapeutic Market
    • 14.7.2 Arrowhead' s NSAID Market Outlook
    • 14.7.3 Arrowhead' s COX-2 Market Outlook
    • 14.7.4 Arrowhead' s Opioid Market Outlook
    • 14.7.5 Arrowhead' s Triptan Market Outlook
    • 14.7.6 Arrowhead' s Non-Traditional/Adjuvant Market Outlook
    • 14.7.7 Arrowhead' s Local Anesthetics Market Outlook
  • 14.8 Summary of the Future Global Pain Therapeutic Market

15 Bibliography

Tables

  • Table 1: Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 2: Current Late Stage Pain Therapeutics Pipeline, June 2010
  • Table 3: Comparison of the Global Pain Therapeutics Market ($m) Revenue by Analgesic Class, 2010 and 2015
  • Table 4: Characteristics and Treatment of Acute versus Chronic Pain
  • Table 5: Heritability Link in a Range of Diseases where Pain is a Predominant Factor
  • Table 6: Incidence of Pain Compared to Other Major Conditions in the US
  • Table 7: Incidence of Painful Conditions in US Households
  • Table 8: WHO Guidelines for Pain Management
  • Table 9: Surgery Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 10: Postoperative Acute Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 11: Late-Stage and Phase II Postoperative Pain Therapeutics Pipeline, 2010
  • Table 12: Common Etiologies Associated with Neuropathic Pain
  • Table 13: Neuropathic Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 14: Neuropathic Pain Therapeutics
  • Table 15: Late-Stage and Phase II Neuropathic Pain Therapeutics Pipeline, 2010
  • Table 16: Fibromyalgia Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 17: Late-Stage and Phase II Fibromyalgia Pain Therapeutics Pipeline, 2010
  • Table 18: Arthritis Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 19: Late-Stage and Phase II Arthritic Pain Therapeutics Pipeline, 2010
  • Table 20: Incidence Rate of Migraine (%) by Gender in the Seven Major Markets, 2010
  • Table 21: Migraine Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 22: Common Analgesics Used for Mild Migraine
  • Table 23: Ergot Alkaloid Derivatives Used for Migraine
  • Table 24: Triptans Used for Migraine
  • Table 25: Late-Stage and Phase Migraine Pain Therapeutics Pipeline, 2010
  • Table 26: Crude Incidence Rate of Cancer by Gender in the Seven Major Markets, 2010
  • Table 27: Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 28: Cancer Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 29: The Oral and Paraental Equivalences and Relative Potency of Opioids Compared with Morphine
  • Table 30: Adjuvant Therapeutics Used in Cancer Pain Management
  • Table 31: Late-Stage and Phase II Cancer Pain Therapeutics Pipeline, 2010
  • Table 32: Low Back Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 33: Late-Stage and Phase II Back Pain Therapeutics Pipeline, 2010
  • Table 34: Potential Pain Biomarkers
  • Table 35: Pain Therapeutics Investigated by fMRI
  • Table 36: Current Late Stage and II Pain Therapeutics Pipeline, June 2010
  • Table 37: Summary of Branded Analgesics Analyzed by Arrowhead Publishers, 2010
  • Table 38: Top-10 Selling Branded Analgesics, 2009 Revenues ($m)
  • Table 39: Revenues of the 2009 and 2008 Top-Selling Analgesics by Drug Classification ($m)
  • Table 40: Worldwide Leading Branded Pain Therapeutic Revenue History ($m), 2004-2009
  • Table 41: Summary of Arrowhead' s Key Pipeline Pain Therapeutics Candidates, 2010
  • Table 42: Worldwide Leading Branded Pain Therapeutic Revenue Forecast ($m), 2010-2015
  • Table 43: Financial Forecast of the NSAID Global Market ($m), 2009-2015
  • Table 44: Financial Forecast of the COX-2 Global Market ($m), 2009-2015
  • Table 45: Financial Forecast of the Opioid Global Market ($m), 2009-2015
  • Table 46: Financial Forecast of the Triptan Global Market ($m), 2009-2015
  • Table 47: Financial Forecast of the Nontraditional/Adjuvant Global Market ($m), 2009-2015
  • Table 48: Financial Forecast of Local Anesthetics Global Market ($m), 2009-2015
  • Table 49: Total Global Pain Therapeutic Market Forecast ($m) by Drug Class, 2009-2015

Figures

  • Figure1: Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 2: Pain Incidence Forecast in the Seven Major Markets, 2010 and 2020
  • Figure 3: Unmet Needs in the Pain Therapeutics Market 26
  • Figure 4: Analgesic Drug Classes Share of the Global Pain Therapeutics Market, 2010
  • Figure 5: Analgesic Drug Classes Share of the Global Pain Therapeutics Market, 2015
  • Figure 6: Schematic Diagram of the Pain Pathway
  • Figure 7: Schematic Diagram of Referred Pain Pathways Involved in an Ischemic Cardiac Attack
  • Figure 8: Schematic Diagram of Variability of Genes at Multiple Sites of the Pain Pathway Contributing to Individual Differences in Pain Processing
  • Figure 9: Examples of Pain Evaluation Models
  • Figure 10: Leading Causes of Pain in the US
  • Figure 11: Surgery Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 12: Postoperative Acute Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 13: World Federation of Societies of Anesthesiologists (WFSA) Analgesic Ladder
  • Figure 14: PROSPECT Postoperative Pain Management Algorithm
  • Figure 15: Neuropathic Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 16: NIH Algorithm for Managing Neuropathic Pain
  • Figure 17: Fibromyalgia Painful Points within the Human Body
  • Figure 18: Fibromyalgia Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 19: Treatment Algorithm for Fibromyalgia
  • Figure 20: Arthritis Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 21: Arthritis Therapeutic Treatment Algorithm
  • Figure 22: Migraine Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 23: European Federation of Neurological Societies (EFNS) 2009 Migraine Treatment Algorithm
  • Figure 24: Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 25: Cancer Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 26: WHO' s Three-Step ' Analgesia Ladder' for Cancer Pain Management
  • Figure 27: Low Back Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 28: Back Pain Treatment Algorithm
  • Figure 29: LidoPAIN BP' s Phase IIa Back Pain Trial Results
  • Figure 30: Schematic Diagram of Blood Oxygenation Level Dependent (BOLD) Concept in MRI
  • Figure 31: SWOT Analysis of the Pain Therapeutics Market, 2010
  • Figure 32: Worldwide Leading Branded Pain Therapeutic Revenue Forecast ($m), 2004-2015
  • Figure 33: Financial Forecast of the NSAID Global Market ($m), 2009-2015
  • Figure 34: Financial Forecast of the COX-2 Global Market ($m), 2009-2015
  • Figure 35: Financial Forecast of the Opioid Global Market ($m), 2009-2015
  • Figure 36: Financial Forecast of the Triptan Global Market ($m), 2009-2015
  • Figure 37: Financial Forecast of the Nontraditional/Adjuvant Global Market ($m), 2009-2015
  • Figure 38: Financial Forecast of Local Anesthetics Global Market ($m), 2009-2015
  • Figure 39: Total Global Pain Therapeutics Market Forecast ($m) by Drug Class, 2009-2015
  • Figure 40: Total Global Pain Therapeutics Market Revenue Forecast ($m), 2009-2015
Back to Top